This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Navidea Biopharmaceuticals Announces The Presentation Of Lymphoseek® Data At Upcoming Scientific Meetings

Stocks in this article: NAVB

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek ® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. Details of the poster presentations are listed below.

   

Conference:

Radiological Society of North America Conference (RSNA)

Date:

November 25-30, 2012

Location:

Chicago

 

Poster Title 1:

In Phase 3 Clinical Studies in Melanoma and Breast Cancer, Receptor-Targeted (CD206) Tc 99m Tilmanocept Provided Enhanced Intraoperative Lymphatic Mapping, Leading to Increased Pathology Findings in Patients and Upstaging in Pathology-Positive Patient

Author:

Frederick Cope, Ph.D., Navidea Biopharmaceuticals

Session, Date:

Poster Sessions, Monday, Nov. 26, 2012, 12:15 – 12:45 p.m.

 

Poster Title 2:

A Phase 3 Clinical Trial Employing Tc 99m Tilmanocept, a Novel CD206-Targeted Intraoperative Lymphatic Mapping Agent For Breast Cancer and Melanoma, Shows Significant Concordance between Preoperative Imaging and Intraoperative Localization of Disease

Author:

Frederick Cope, Ph.D., Navidea Biopharmaceuticals

Session, Date:

Poster Sessions, Wednesday, Nov. 28, 2012, 12:45 – 1:15 p.m.

 

Conference:

CTRC-AACR San Antonio Breast Cancer Symposium

Date:

December 4-8, 2012

Location:

San Antonio, Texas

 

Poster Title:

Tc 99m Tilmanocept and Sulfur Colloid Injection: A comparison of Preoperative Imaging and Intraoperative Lymphatic Mapping of Breast Cancer Patients – Localization Rate and Degree of Localization

Author:

Frederick Cope, Ph.D., Navidea Biopharmaceuticals

Session, Date:

Poster Session 1, Wednesday, Dec. 5, 2012, 5 – 7 p.m.

 

About Lymphoseek ®

Lymphoseek ® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancers such as breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs